Loading stock data…
$15.41-0.11 (-0.73%)
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Summit Therapeutics Inc. in the Healthcare sector is trading at $15.41 with a market capitalization of $10.5B. Wall Street consensus targets $29.82 (13 analysts), implying a +93.5% move over the next 12 months. The stock is currently near its 52-week low of $12.07, remaining 5.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$220.50M↓ | -$195.21M↑ | -$224.88M↑ | -$234.21M↑ | -$568.44M |
| Net Income | -$215.70M↓ | -$189.42M↑ | -$219.17M↑ | -$231.79M↑ | -$565.71M |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...